Abstract Search

ea0098c10 | Clinical – Chemo/SSA/Biologics | NANETS2023

An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

Gambardella Valentina , Capdevila Jaume , Kuboki Yasutoshi , B Alese Olatunji , Morgensztern Daniel , Sayehli Cyrus , F Sanmamed Miguel , Arriola Edurne , Wolf Jurgen , Owonikoko Taofeek , Bouzaggou Mohamed , Song Eric , Studeny Matus , Wermke Martin

Background: Delta-like ligand 3 (DLL3) is highly expressed on small-cell lung cancer (SCLC) tumors and neuroendocrine carcinomas (NECs). BI 764532 is a DLL3/CD3 IgG-like T-cell engager with potent preclinical activity. NCT04429087 is an ongoing phase I dose-escalation trial of BI 764532 in adults with locally advanced/metastatic DLL3-positive (confirmed centrally) SCLC, extrapulmonary NEC, or large cell neuroendocrine lung carcinoma. Here we focus on patients with extrapulmona...

0 shares

Endocrine Abstracts

An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

BiosciAbstracts